Diplomat Pharmacy, Inc. (DPLO)
Lifshitz & Miller announces investigation on behalf of DPLO investors. The investigation concerns whether DPLO violated federal securities laws by issuing false and misleading statements concerning its calculation of DIR fees and performance of DPLO's hepatitis C segment.
If you are a DPLO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at email@example.com.